Evidence map›Paper›PMID 33116630›Full record

ArticleOncoTargets and therapy2020

ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway.

Xiang Zhu, An Xu, Yang Zhang, Nan Huo, Rui Cong, Luyuan Ma, Zhong Chu, Zhi Tang, Xiaofeng Kang, Shaozhong Xian and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiang Zhu *Department of Infectious Disease, Army No.82 Group Military Hospital, Baoding, People's Republic of China.
An Xu *Department of Oncology, Second Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
Yang Zhang *Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.ORCID 0000-0002-2504-3117
Nan HuoDepartment of Cellular Engineering Lab, Beijing Institute of Biotechnology, Beijing, People's Republic of China.
Rui CongDepartment of Cellular Engineering Lab, Beijing Institute of Biotechnology, Beijing, People's Republic of China.ORCID 0000-0001-6180-8570
Luyuan MaDepartment of Cellular Engineering Lab, Beijing Institute of Biotechnology, Beijing, People's Republic of China.
Zhong ChuDepartment of Cellular Engineering Lab, Beijing Institute of Biotechnology, Beijing, People's Republic of China.
Zhi TangDepartment of Cellular Engineering Lab, Beijing Institute of Biotechnology, Beijing, People's Republic of China.
Xiaofeng KangDepartment of Cellular Engineering Lab, Beijing Institute of Biotechnology, Beijing, People's Republic of China.
Shaozhong XianDepartment of Urology, Beijing Luhe Hospital, Capital Medical University, Beijing, People's Republic of China.
Xiaojie XuDepartment of Cellular Engineering Lab, Beijing Institute of Biotechnology, Beijing, People's Republic of China.
Beijing Luhe Hospital Affiliated to Capital Medical University · CNChinese PLA General Hospital · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal cell cancer (RCC) is one of the most lethal malignancies of the kidney in adults. mTOR (mammalian target of rapamycin) signaling pathway plays a pivotal role in RCC tumorigenesis and progression and inhibitors targeting the mTOR pathway have been widely used in advanced RCC treatment. Therefore, it is of great significance to explore the potential regulators of the mTOR pathway as RCC therapeutic targets. MATERIALS AND

methodsBioinformatics analysis was used to screen out the most significant differentially expressed genes in the RCC dataset of The Cancer Genome Atlas (TCGA). Real-time PCR and Western-blot analysis were utilized to examine the expression of inositol-1,4,5-trisphosphate-3-kinase-A (ITPKA) in four RCC cell lines and one human embryonic kidney cell line. Cell counting Kit-8 and colony formation assay were performed to estimate the effect of ITPKA on the proliferation ability of RCC cells. Wound healing and Transwell assays were used to test the effect of ITPKA on RCC cell migration and invasion. Xenograft formation assay was performed in nude mice to investigate the effect of ITPKA in vivo. mTORC1 pathway inhibitor was added to explore the mechanisms by which ITPKA regulates RCC cell growth and progression.

resultsBased on bioinformatics analysis, ITPKA is screened out as one of the most significant differentially expressed genes in RCC. ITPKA is upregulated and positively correlated with RCC malignancy and poorer prognosis. ITPKA promotes RCC growth, migration and invasion in cultured cells, and accelerates tumor growth in nude mice. Mechanistically, ITPKA stimulates the mTORC1 signaling pathway which is a requirement for ITPKA modulation of RCC cell proliferation, migration and invasion.

conclusionOur data demonstrate a critical regulatory role of the ITPKA in RCC and suggest that ITPKA/mTORC1 axis may be a promising target for diagnosis and treatment of RCC.

Indexed as

growthITPKA1migration and invasionmTORC1 pathwayRCC

Identifiers

PMID33116630
PMCPMC7573328
OpenAlexW3092890372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.